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Introduction 
Mitochondria are semiautonomous, double 
membrane-bound organelles, which produce cellular 
energy via aerobic respiration. This task is executed 
by the protein machinery of the oxidative 
phosphorylation (OXPHOS) system, located at the 
inner mitochondrial membrane (IMM). In this 
system, four large multi-protein complexes transport 
electrons from reduced coenzymes (NADH and 
FADH2) to molecular oxygen (O2) via sequential 
redox reactions. This transport is coupled to the 
vectorial outward translocation of protons (H
+
) 
across the IMM at complex I, III and IV. The H
+
 
gradient generated by this translocation, and the 
ensuing inward-negative mitochondrial membrane 
potential across the IMM (∆ᴪ), provide the driving 
force for ATP synthesis at complex V [1]. 
Importantly, dysfunction of the OXPHOS system is 
generally associated with severe progressive 
disorders that can display their first onset at any age.  
Mitochondrial diseases in children constitute a 
diagnostic and therapeutic challenge for the clinician. 
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The majority of the early onset forms of these 
diseases are caused by an isolated malfunction of 
mitochondrial complex I (NADH:ubiquinone 
oxidoreductase) [2, 3, 4]. This respiratory chain 
complex  represents the main entry point of electrons 
into the OXPHOS system. It is composed of 45 
subunits of which seven are encoded by the 
mitochondrial DNA (mtDNA) and 38 by the nuclear 
DNA (nDNA).
 
Disease-causing mutations have been 
identified in all of the mtDNA genes and several of 
the nDNA genes encoding structural subunits of 
complex I [4]. In addition to the 45 structural 
components, several assembly factors are needed to 
allow proper biogenesis of complex I [5]. During the 
last years, disease-causing mutations have also been 
identified in complex I assembly factors.   
Isolated, nDNA-encoded complex I deficiency 
generally causes Leigh syndrome (also known as 
subacute necrotizing encephalomyelopathy), which is 
one of the mitochondrial diseases with a very poor 
prognosis [4]. The disease mainly manifests in the 
central nervous system, typically causing 
symmetrical lesions in the basal ganglia or brain 
stem. However, also cases with extensive 
leukodystrophy have been reported [4]. Clinical 
symptoms include loss of previously acquired motor 
skills, disturbed eye movements and/or loss of visual 
contact, episodic vomiting, seizures and irritability. 
In most cases, Leigh syndrome is inherited as an 
autosomal recessive trait. However, X-linked 
recessive and mitochondrial inheritance have also 
been reported [6].  
Although research is ongoing, there is no cure yet for 
Leigh syndrome but supportive treatment may help to 
reduce symptoms or delay the progression of the 
disease. Ideally, this treatment should be 
individualized for each patient, as every child is 
clinically and genetically different. Therefore, 
detailed insights into the consequences of Leigh 
syndrome at the cellular level are required.  
During the last years, we have developed and applied 
live cell microscopy techniques to quantify  key 
biochemical parameters in cells from Leigh 
syndrome patients. These approaches were primarily 
set up for patient skin fibroblasts, which are usually 
easy to obtain and therefore frequently used for 
diagnostic purposes in children with a suspected 
mitochondrial deficiency. Our patient cohort 
consisted of 15 children with isolated, nDNA-
encoded complex I deficiency (for an extensive 
review see Distelmaier et al., 2009) [4]. Mutations 
were established in several complex I subunits 
including the NDUFV1 subunit (two patients), the 
NDUFS1 subunit (one patient), the NDUFS2 subunit 
(four patients), the NDUFS4 subunit (five patients), 
the NDUFS7 subunit (one patient) and the NDUFS8 
subunit (two patients). All patients displayed a 
complex I deficiency in skin fibroblasts and muscle 
tissue, suffered from Leigh/Leigh-like syndrome and 
died during the first years of live.  Below we will 
briefly discuss the key findings that we obtained in 
the patient cells.  
 
Reactive oxygen species levels in Leigh syndrome 
patient fibroblasts 
Importantly, (dys)function of the mitochondrial 
respiratory chain is regarded as an important source 
of cellular reactive oxygen species (ROS) [7]. 
Therefore, mitochondrial constituents like proteins, 
lipids and mtDNA are exposed to oxidative stress and 
might be damaged/impaired over time. Although 
ROS also have important physiological functions 
within organisms (e.g. cellular signaling), sustained 
ROS-induced damage likely will negatively affect 
cell biological processes if not properly 
counterbalanced by repair mechanisms. During 
conditions of mitochondrial dysfunction this 
damage/repair balance may already be disturbed at an 
early stage. Using live cell imaging microscopy we 
demonstrated that the rate of oxidation of two ROS-
sensitive chemical reporter molecules, hydroethidine 
(HEt) and CM-H2DCF (5-(and-6)-chloromethyl-2',7'-
dichlorodihydro fluorescein), was significantly 
increased in skin fibroblasts from Leigh syndrome 
patients [8, 9]. Importantly, an inverse relationship 
with the amount and residual activity of complex I 
was observed (e.g. higher cellular ROS levels were 
found in cells with a lower residual complex I 
activity and vice versa).  
 
Mitochondrial membrane potential in Leigh 
syndrome patient fibroblasts  
As explained above, the inward-negative potential 
across the IMM () is co-sustained by the action of 
complex I. This potential is regarded as a key-
indicator of mitochondrial health because it is 
required to drive ATP synthesis and many other 
mitochondrial functions. Obviously, complex I 
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dysfunction may disturb its proton-translocating 
ability, leading to a less negative (depolarized) . 
We developed a sensitive method to estimate  in 
living skin fibroblasts [10, 11]. This revealed a 
depolarized membrane potential in all patient cell 
lines investigated [12]. Of note, controlled leak of 
protons via mitochondrial uncoupling proteins 
(UCPs) might function as a regulator of increased 
ROS production [13]. Compatible with this idea, 
regression analysis revealed a linear correlation 
between extent of depolarization and the levels 
superoxide-derived ROS  (e.g. the higher the ROS 
levels the more depolarized ) [12].  
 
Mitochondrial dynamics in Leigh syndrome patient 
fibroblasts 
In living cells, mitochondria are often not bean-
shaped but form a filamentous network that is 
constantly remodeled by fusion and fission events. It 
appears that these dynamics are crucial for proper 
mitochondrial function and are related to the ROS 
levels and/or metabolic state of the cell. 
Quantification of mitochondrial structure in 
fibroblasts of Leigh syndrome patients revealed that 
mitochondrial shape and number were normal in cells 
with a moderate complex I deficiency (Class II), 
whereas mitochondrial were fragmented in cells with 
a more severe complex I deficiency (Class I) [14]. 
Interestingly, cellular ROS levels were much higher 
in Class I patient cells suggesting that Leigh 
syndrome patient cell lines with a fragmented 
mitochondrial morphology have possibly surpassed a 
certain threshold of oxidative stress.  
 
ATP homeostasis in Leigh syndrome patient 
fibroblasts  
OXPHOS-mediated ATP synthesis in respiring cells 
clearly depends on the proper function of the 
involved protein complexes and the maintenance of 
 (see above). Accordingly, we studied 
mitochondrial ATP production in Leigh syndrome 
patient fibroblasts, stimulated with the hormone 
bradykinin (Bk). To this end, we measured the ATP-
dependent luminescence signal of a mitochondria 
targeted ATP-sensitive protein (luciferase) using a 
very sensitive photomultiplier tube (PMT) detection 
system. We observed that the Bk-stimulated increase 
in mitochondrial ATP concentration was reduced in 
most of the patient cell lines [15]. Regression 
analysis revealed a close relationship between this 
increase and cellular ROS levels as well as  
(details are reviewed in Valsecchi et al., 2009) [12, 
16].   
 
Calcium homeostasis in Leigh syndrome patient 
fibroblasts 
A sufficient supply of ATP is crucial to maintain 
proper cell functioning. The latter includes the 
continuous action of ATPases that remove ionic 
calcium (Ca
2+
), a key cellular signalling molecule,  
from the cytosol towards the endoplasmatic reticulum 
(ER) [17]. We investigated cellular Ca
2+
 homeostasis 
by measuring the cytosolic free Ca
2+
 concentration 
(using the fluorescent Ca
2+
 indicator fura-2) and the 
ER Ca
2+
 content under resting and Bk-stimulated 
conditions. Additionally, we quantified the Ca
2+
-
dependent luminescence signal of a mitochondria 
targeted Ca
2+
-sensitive protein (aequorin) using a 
PMT detection system [15, 18, 19, 20]. It was found 
that the ER Ca
2+
 content was reduced in several 
patient cell lines under resting conditions. As a 
consequence, the amplitude of the cytosolic and 
mitochondrial Bk-induced Ca
2+
 peaks were reduced. 
In agreement with these results, the rate of ATP-
dependent refilling of the ER with Ca
2+
 was also 
reduced. These observations support a model in 
which impaired ATP production by the OXPHOS 
system leads to a reduced fueling of the ATPases of 
the intracellular Ca
2+
 stores. The latter then leads to a 
disturbed Ca
2+
 signaling upon cell stimulation with 
Bk. Of note, evidence was provided that an increase 
in mitochondrial Ca
2+
 concentration stimulates 
OXPHOS-mediated ATP production. It is expected 
that complex I deficiency hampers this process and 
thereby leads to disturbances in ATP supply upon 
cell stimulation (details are reviewed in Willems et 
al., 2008 and Valsecchi et al., 2009) [16, 20].  
 
Implications for future research 
The data presented above illustrate some important 
cellular consequences of complex I dysfunction. 
Given their interdependence, it will be a challenge to 
mitigate or prevent these consequences using drug 
therapy. However, this task might be facilitated by 
studying recently developed animal models of Leigh 
syndrome [21]. Thus far, some potential treatment 
strategies for Leigh syndrome have been applied. 
These strategies include prescription of vitamins and 
food supplements, including coenzyme Q10, thiamine, 
riboflavin, vitamin E and L-carnitine [22, 23]. 
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Additionally, a ketogenic diet might also be useful. 
However, the therapeutic effects of these approaches 
are generally unsatisfactory, especially on the long 
term. In our cell experiments we tested the water-
soluble vitamin E analogue Trolox, which is a potent 
antioxidant, and observed beneficial effects in certain 
patient cell lines [24]. Importantly, patient fibroblasts 
with a moderate complex I deficiency (e.g. 
considerable residual complex I activity, rather low 
reactive oxygen species levels, normal mitochondrial 
morphology, etc.) benefited from chronic Trolox 
treatment whether patient cell lines with a severe 
deficiency (very low residual complex I activity, high 
reactive oxygen species levels, etc.) responded less 
well to this treatment. These findings might have 
important implications for antioxidant treatment of 
Leigh syndrome patients and may explain apparent 
differences in clinical response to drug therapy. In 
addition, our live cell data suggest that modulators of 
cellular Ca
2+
 homeostasis might be of interest in the 
treatment of Leigh syndrome. For instance, the drug 
CGP-37157, which is a blocker of mitochondrial Ca
2+
 
export,  improved Bk-stimulated mitochondrial ATP 
levels in skin fibroblasts of Leigh syndrome patients 
[18]. 
 
Currently, supportive therapy is still a key element of 
the treatment for Leigh syndrome patients. General 
aspects include supplementation of sufficient 
calories, fluids and electrolytes. Because of feeding 
problems, percutaneous endoscopic gastrostomy is 
frequently required. It is crucial to avoid periods of 
fasting and catabolism. Accordingly, during episodes 
of infections (especially if they manifest with fever) 
intravenous supplementation of glucose and fat might 
be required. Patients frequently develop seizures and 
antiepileptic therapy is often necessary. Importantly, 
drugs that possibly affect mitochondrial function 
should be strictly avoided (e.g. sodium valproate, 
barbiturates, tetracyclines and chloramphenicol). 
Moreover, physical therapy is a crucial part of 
supportive therapy. Finally, for parents considering 
having other children, genetic counseling might be 
available, especially if the genetic cause of the 
disease is identified.  
Future studies with patient material in combination 
with animal models of mitochondrial complex I 
deficiency will hopefully expand our understanding 
of mitochondrial genetics and function. This might 
lead to more specific and targeted therapies that will 
improve patient care and increase the quality of life 
for children affected with Leigh syndrome.  
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